A9613 HCPCS code: Piflufolastat f 18 (pylarify truvu), diagnostic, 1 millicurie
A9613 is the HCPCS Level II code for piflufolastat f 18 (pylarify truvu), diagnostic, 1 millicurie. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case.
Code details
| Field | Value |
|---|---|
| Section | A codes — Transportation, medical/surgical supplies and miscellaneous |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 57 |
| BETOS category | I1E |
| Added | 2026-10-01 |
| Last action effective | 2026-10-01 |
What changed for A9613
- October 2026: Code appears in this HCPCS release
- 2026-10-01: A9613 added to HCPCS Level II
- 2026-10-01: Last CMS action: code added
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code A9613?
A9613 is the HCPCS Level II code for piflufolastat f 18 (pylarify truvu), diagnostic, 1 millicurie. Short descriptor: "F 18 pylarify truvu, dx 1mci".
Does Medicare cover A9613?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related A96 codes
- A9600 — Strontium sr-89 chloride, therapeutic, per millicurie
- A9601 — Flortaucipir f 18 injection, diagnostic, 1 millicurie
- A9602 — Fluorodopa f-18, diagnostic, per millicurie
- A9603 — Injection, pafolacianine, 0.1 mg
- A9604 — Samarium sm-153 lexidronam, therapeutic, per treatment dose, up to 150 millicuries
- A9606 — Radium ra-223 dichloride, therapeutic, per microcurie
- A9607 — Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie
- A9608 — Flotufolastat f 18, diagnostic, 1 millicurie
- A9609 — Fludeoxyglucose f18 up to 15 millicuries
- A9610 — Xenon xe-129 hyperpolarized gas, diagnostic, per study dose
- A9611 — Flurpiridaz f 18, diagnostic, 1 millicurie
- A9612 — Injection, fluorescein, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under A9613
- Watch A9613 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for A9613
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.